Magnus Essand

Summary

Publications

  1. pmc Adenovirus serotype 5 vectors with Tat-PTD modified hexon and serotype 35 fiber show greatly enhanced transduction capacity of primary cell cultures
    Di Yu
    Department of Immunology, Genetics and Pathology, Science for Life Laboratory, Uppsala University, Uppsala, Sweden
    PLoS ONE 8:e54952. 2013
  2. pmc Systemic treatment with CAR-engineered T cells against PSCA delays subcutaneous tumor growth and prolongs survival of mice
    Victoria Hillerdal
    Department of Immunology, Genetics and Pathology, Rudbeck Laboratory, Uppsala University SE 75185 Uppsala, Sweden
    BMC Cancer 14:30. 2014
  3. ncbi request reprint Virotherapy of neuroendocrine tumors
    Magnus Essand
    Rudbeck Laboratory, Department of Immunology, Genetics and Pathology, Uppsala University, Uppsala, Sweden
    Neuroendocrinology 97:26-34. 2013
  4. pmc Genetically engineered T cells for the treatment of cancer
    M Essand
    Department of Immunology, Genetics and Pathology, Uppsala University, Uppsala, Sweden
    J Intern Med 273:166-81. 2013
  5. doi request reprint Oncolytic viruses for the treatment of neuroendocrine tumors
    M Essand
    Department of Immunology, Genetics and Pathology, Science for Life Laboratory, Uppsala University, Sweden
    Horm Metab Res 43:877-83. 2011
  6. doi request reprint Midgut carcinoid patients display increased numbers of regulatory T cells in peripheral blood with infiltration into tumor tissue
    Sofia Vikman
    Division of Clinical Immunology, Rudbeck Laboratory, Uppsala University, Uppsala, Sweden
    Acta Oncol 48:391-400. 2009
  7. doi request reprint Strategic use of an adenoviral vector for rapid and efficient ex vivo-generation of cytomegalovirus pp65-reactive cytolytic and helper T cells
    Ole Forsberg
    Clinical Immunology Division, Rudbeck Laboratory, Uppsala University, Uppsala, Sweden
    Br J Haematol 141:188-99. 2008
  8. ncbi request reprint CpG therapy is superior to BCG in an orthotopic bladder cancer model and generates CD4+ T-cell immunity
    Sara M Mangsbo
    Division of Clinical Immunology, Rudbeck Laboratory, Uppsala University, Uppsala, Sweden
    J Immunother 31:34-42. 2008
  9. ncbi request reprint Adenovirus-mediated CD40 ligand therapy induces tumor cell apoptosis and systemic immunity in the TRAMP-C2 mouse prostate cancer model
    Helena Dzojic
    Clinical Immunology Division, Rudbeck Laboratory, Uppsala University, Uppsala, Sweden
    Prostate 66:831-8. 2006
  10. ncbi request reprint CpG oligonucleotide therapy cures subcutaneous and orthotopic tumors and evokes protective immunity in murine bladder cancer
    Christina Ninalga
    Rudbeck Laboratory, Clinical Immunology Division, Uppsala University, 751 85 Uppsala, Sweden
    J Immunother 28:20-7. 2005

Collaborators

Detail Information

Publications33

  1. pmc Adenovirus serotype 5 vectors with Tat-PTD modified hexon and serotype 35 fiber show greatly enhanced transduction capacity of primary cell cultures
    Di Yu
    Department of Immunology, Genetics and Pathology, Science for Life Laboratory, Uppsala University, Uppsala, Sweden
    PLoS ONE 8:e54952. 2013
    ....
  2. pmc Systemic treatment with CAR-engineered T cells against PSCA delays subcutaneous tumor growth and prolongs survival of mice
    Victoria Hillerdal
    Department of Immunology, Genetics and Pathology, Rudbeck Laboratory, Uppsala University SE 75185 Uppsala, Sweden
    BMC Cancer 14:30. 2014
    ..The prostate stem cell antigen (PSCA) is a protein expressed on the surface of prostate epithelial cells as well as in primary and metastatic prostate cancer cells and therefore a promising target for immunotherapy of prostate cancer...
  3. ncbi request reprint Virotherapy of neuroendocrine tumors
    Magnus Essand
    Rudbeck Laboratory, Department of Immunology, Genetics and Pathology, Uppsala University, Uppsala, Sweden
    Neuroendocrinology 97:26-34. 2013
    ..In addition, it points out the advantages and shortcomings of using replicating viruses in the treatment of cancer and addresses research fields that can increase the efficacy of virus-based therapy...
  4. pmc Genetically engineered T cells for the treatment of cancer
    M Essand
    Department of Immunology, Genetics and Pathology, Uppsala University, Uppsala, Sweden
    J Intern Med 273:166-81. 2013
    ..Here we review the recent progress in the field, and summarize the challenges that lie ahead and the strategies being used to overcome them...
  5. doi request reprint Oncolytic viruses for the treatment of neuroendocrine tumors
    M Essand
    Department of Immunology, Genetics and Pathology, Science for Life Laboratory, Uppsala University, Sweden
    Horm Metab Res 43:877-83. 2011
    ..This article reviews the recent literature on oncolytic viruses used so far for neuroendocrine tumors and indicates important issues to focus on in the future...
  6. doi request reprint Midgut carcinoid patients display increased numbers of regulatory T cells in peripheral blood with infiltration into tumor tissue
    Sofia Vikman
    Division of Clinical Immunology, Rudbeck Laboratory, Uppsala University, Uppsala, Sweden
    Acta Oncol 48:391-400. 2009
    ..Cancer patients generally display suppressed Th1-type immunity that disables mounting of an efficient anti-tumor response. However, little is known about patients with neuroendocrine midgut carcinoids...
  7. doi request reprint Strategic use of an adenoviral vector for rapid and efficient ex vivo-generation of cytomegalovirus pp65-reactive cytolytic and helper T cells
    Ole Forsberg
    Clinical Immunology Division, Rudbeck Laboratory, Uppsala University, Uppsala, Sweden
    Br J Haematol 141:188-99. 2008
    ..6-fold to 4.3% for CD8+ T cells and 25.8-fold to 6.5% for CD4+ T cells. This implies that sufficient number of pp65-specific cytolytic and helper T cells for adoptive transfer may be obtained in only 2 weeks...
  8. ncbi request reprint CpG therapy is superior to BCG in an orthotopic bladder cancer model and generates CD4+ T-cell immunity
    Sara M Mangsbo
    Division of Clinical Immunology, Rudbeck Laboratory, Uppsala University, Uppsala, Sweden
    J Immunother 31:34-42. 2008
    ..Taken together, our data suggest that CpGs are superior to BCG for bladder cancer immunotherapy. Thus, this potent new drug may be an attractive therapeutic alternative and should be evaluated in bladder cancer patients...
  9. ncbi request reprint Adenovirus-mediated CD40 ligand therapy induces tumor cell apoptosis and systemic immunity in the TRAMP-C2 mouse prostate cancer model
    Helena Dzojic
    Clinical Immunology Division, Rudbeck Laboratory, Uppsala University, Uppsala, Sweden
    Prostate 66:831-8. 2006
    ..We investigated the anti-tumor effects induced by CD40L gene transfer into the mouse prostate adenocarcinoma cell line TRAMP-C2, both in vitro and in vivo...
  10. ncbi request reprint CpG oligonucleotide therapy cures subcutaneous and orthotopic tumors and evokes protective immunity in murine bladder cancer
    Christina Ninalga
    Rudbeck Laboratory, Clinical Immunology Division, Uppsala University, 751 85 Uppsala, Sweden
    J Immunother 28:20-7. 2005
    ..Our results show that CpG ODN therapy cures established subcutaneous and orthotopic bladder cancer via a T(H)1-mediated response and provides long-lasting protective immunity...
  11. doi request reprint High frequency of prostate antigen-directed T cells in cancer patients compared to healthy age-matched individuals
    Ole Forsberg
    Clinical Immunology Division, Rudbeck Laboratory, Uppsala University, Uppsala, Sweden
    Prostate 69:70-81. 2009
    ..In order to obtain a sustained cytotoxic T lymphocyte (CTL) response against cancer cells it is preferable to have CTLs directed against multiple peptide epitopes from numerous tumor-associated antigens...
  12. pmc T cells engineered with a T cell receptor against the prostate antigen TARP specifically kill HLA-A2+ prostate and breast cancer cells
    Victoria Hillerdal
    Department of Immunology, Genetics, and Pathology, Science for Life Laboratory, Uppsala University, Uppsala, Sweden
    Proc Natl Acad Sci U S A 109:15877-81. 2012
    ..To our knowledge this report on engineering of T cells with a TCR directed against an antigen specifically expressed by prostate cells is unique...
  13. ncbi request reprint CD8+ T cells against multiple tumor-associated antigens in peripheral blood of midgut carcinoid patients
    Sofia Vikman
    Division of Clinical Immunology, Rudbeck Laboratory, Uppsala University, Uppsala, Sweden
    Cancer Immunol Immunother 57:399-409. 2008
    ..CD8(+) T cells recognizing tumor-associated antigen (TAA) epitopes are of great interest for the establishment of immunotherapy as a novel treatment for this type of malignancy...
  14. ncbi request reprint A novel TARP-promoter-based adenovirus against hormone-dependent and hormone-refractory prostate cancer
    Wing Shing Cheng
    Clinical Immunology, Rudbeck Laboratory, Uppsala University, SE 75185, Uppsala, Sweden
    Mol Ther 10:355-64. 2004
    ..Therefore, we believe that an adenovirus with therapeutic gene expression controlled by an insulator-shielded PPT sequence is a promising candidate for gene therapy of prostate cancer...
  15. pmc Double-detargeted oncolytic adenovirus shows replication arrest in liver cells and retains neuroendocrine cell killing ability
    Justyna Leja
    Division of Clinical Immunology, Rudbeck Laboratory, Uppsala University, Uppsala, Sweden
    PLoS ONE 5:e8916. 2010
    ..Herein, we explore miRNA-based regulation of E1A expression as a complementary mechanism to promoter-based transcriptional control...
  16. ncbi request reprint Gene therapy and immunotherapy of prostate cancer: adenoviral-based strategies
    Magnus Essand
    Clinical Immunology Division, Rudbeck Laboratory, Uppsala University, Sweden
    Acta Oncol 44:610-27. 2005
  17. ncbi request reprint The immunotherapy of prostate and bladder cancer
    Thomas H Totterman
    Clinical Immunology Division, Department of Oncology, Radiology and Clinical Immunology, Rudbeck Laboratory, Uppsala University Hospital, Uppsala, Sweden
    BJU Int 96:728-35. 2005
    ..Here we review some timely aspects of tumour immunology, and describe the current status and development of immunotherapy in prostate and bladder cancer...
  18. ncbi request reprint Simultaneous generation of cytomegalovirus-specific CD8+ and CD4+ T lymphocytes by use of dendritic cells comodified with pp65 mRNA and pp65 protein
    Bjorn Carlsson
    Division of Clinical Immunology, Rudbeck Laboratory, Uppsala University, Uppsala, Sweden
    J Infect Dis 192:1912-20. 2005
    ..The approach outlined in the present study can be adapted for a clinical protocol that circumvents potential virus-related biohazards and is available to all patients independently of their human leukocyte antigen haplotype...
  19. pmc Adenovirus with hexon Tat-protein transduction domain modification exhibits increased therapeutic effect in experimental neuroblastoma and neuroendocrine tumors
    Di Yu
    Department of Immunology, Genetics and Pathology, Uppsala University, SE 75185 Uppsala, Sweden
    J Virol 85:13114-23. 2011
    ..Our data suggest that modification of Ad5 with Tat-PTD in HVR5 expands its utility as an oncolytic agent...
  20. pmc An infection-enhanced oncolytic adenovirus secreting H. pylori neutrophil-activating protein with therapeutic effects on neuroendocrine tumors
    Mohanraj Ramachandran
    Department of Immunology, Genetics and Pathology, Uppsala University, Uppsala, Sweden
    Mol Ther 21:2008-18. 2013
    ..Our observations suggest that HP-NAP can serve as a potent immunomodulator in promoting antitumor immune response in the tumor microenvironment and enhance the therapeutic effect of oncolytic adenovirus...
  21. ncbi request reprint Characterization of human prostate and breast cancer cell lines for experimental T cell-based immunotherapy
    Bjorn Carlsson
    Clinical Immunology, Rudbeck Laboratory, Uppsala University, Uppsala, Sweden
    Prostate 67:389-95. 2007
    ....
  22. pmc Tat-PTD-modified oncolytic adenovirus driven by the SCG3 promoter and ASH1 enhancer for neuroblastoma therapy
    Chuan Jin
    Department of Immunology, Genetics, and Pathology, Science for Life Laboratory, Uppsala University, Uppsala SE 75185, Sweden
    Hum Gene Ther 24:766-75. 2013
    ..Furthermore, it delays tumor growth and thereby prolonged survival for nude mice harboring subcutaneous human neuroblastoma xenograft. In conclusion, we report a novel oncolytic adenovirus with potential use for neuroblastoma therapy...
  23. ncbi request reprint Generation of cytotoxic T lymphocytes specific for the prostate and breast tissue antigen TARP
    Bjorn Carlsson
    Clinical Immunology, Rudbeck Laboratory, Uppsala University, Uppsala, Sweden
    Prostate 61:161-70. 2004
    ..We have evaluated TARP for human leukocyte antigen (HLA)-A*0201-restricted peptides capable of triggering TARP-specific CTL...
  24. ncbi request reprint A novel chromogranin-A promoter-driven oncolytic adenovirus for midgut carcinoid therapy
    Justyna Leja
    Division of Clinical Immunology, Rudbeck Laboratory, Uppsala University, Uppsala, Sweden
    Clin Cancer Res 13:2455-62. 2007
    ..We therefore constructed Ad[CgA-E1A], a novel replication-selective oncolytic adenovirus, where the chromogranin A (CgA) promoter controls expression of the adenoviral E1A gene...
  25. doi request reprint Novel markers for enterochromaffin cells and gastrointestinal neuroendocrine carcinomas
    Justyna Leja
    Division of Clinical Immunology, Rudbeck Laboratory, Uppsala University, Uppsala, Sweden
    Mod Pathol 22:261-72. 2009
    ..We verified six novel marker genes that may be developed as biomarkers and/or therapeutic targets...
  26. pmc The HDAC inhibitor FK228 enhances adenoviral transgene expression by a transduction-independent mechanism but does not increase adenovirus replication
    Angelika Danielsson
    Department of Immunology, Genetics and Pathology, Science for Life Laboratory, Uppsala University, Uppsala, Sweden
    PLoS ONE 6:e14700. 2011
    ..Furthermore, since histone deacetylase inhibitors may affect the differentiation of cells, it is important to keep in mind that the activity and specificity of tissue- and tumor-specific promoters may also be affected...
  27. ncbi request reprint Gene expression in midgut carcinoid tumors: potential targets for immunotherapy
    Sofia Vikman
    Division of Clinical Immunology, Uppsala University, Uppsala, Sweden
    Acta Oncol 44:32-40. 2005
    ..This study elucidates that TPH1, VMAT1, and Survivin should be further investigated as potential target antigens for T cell-mediated immunotherapy of midgut carcinoids...
  28. ncbi request reprint Adenovirus CD40 ligand gene therapy counteracts immune escape mechanisms in the tumor Microenvironment
    Angelica Loskog
    Clinical Immunology Division, Rudbeck Laboratory, Uppsala University, Uppsala, Sweden
    J Immunol 172:7200-5. 2004
    ..Our results argue for using adenovirus CD40L gene transfer, alone or in combination with other modalities, for the treatment of Th2-dominated tumors...
  29. pmc CAR/FoxP3-engineered T regulatory cells target the CNS and suppress EAE upon intranasal delivery
    Moa Fransson
    Department of Immunology, Genetics and Pathology, Uppsala University, Uppsala, Sweden
    J Neuroinflammation 9:112. 2012
    ..Here, we propose gene engineering to achieve CNS-targeting Tregs from naïve CD4 cells and demonstrate their efficacy in the EAE model...
  30. doi request reprint A hexon and fiber-modified adenovirus expressing CD40L improves the antigen presentation capacity of dendritic cells
    Lina Liljenfeldt
    Department of Immunology, Genetics and Pathology, Uppsala University, Uppsala, Sweden
    J Immunother 37:155-62. 2014
    ....
  31. ncbi request reprint Characterization of the androgen-regulated prostate-specific T cell receptor gamma-chain alternate reading frame protein (TARP) promoter
    Wing Shing Cheng
    Clinical Immunology, Rudbeck Laboratory, Uppsala University, SE 75185 Uppsala, Sweden
    Endocrinology 144:3433-40. 2003
    ..Thus, our studies define a regulatory sequence that may be used to restrict expression of therapeutic genes to prostate cancer cells and may therefore play a role in prostate cancer gene therapy...
  32. ncbi request reprint Ex vivo stimulation of cytomegalovirus (CMV)-specific T cells using CMV pp65-modified dendritic cells as stimulators
    Bjorn Carlsson
    Clinical Immunology Division, Rudbeck Laboratory, Uppsala University, Uppsala, Sweden
    Br J Haematol 121:428-38. 2003
    ..DC transduced with adenoviral vectors to express full-length antigens may prove to be potent vaccines against viral pathogens and cancer...
  33. doi request reprint Islet engraftment and revascularization in clinical and experimental transplantation
    Christian Molnar
    Department of Immunology, Genetics and Pathology, Uppsala University, Uppsala, Sweden
    Cell Transplant 22:243-51. 2013
    ..Also, formation of an extensive intraislet capillary network, similar to that seen in native islets in the pancreas, was seen after clinical islet transplantation...